Premium
Regulatory status on the role of in vitro dissolution testing in quality control and biopharmaceutics in Europe
Author(s) -
Limberg Jobst,
Potthast Henrike
Publication year - 2013
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.1844
Subject(s) - biopharmaceutics , bioequivalence , biopharmaceutics classification system , dissolution , pharmacology , in vitro , ivivc , dissolution testing , product (mathematics) , in vitro toxicology , chemistry , biochemical engineering , risk analysis (engineering) , business , computer science , bioavailability , medicine , mathematics , biochemistry , engineering , pharmacognosy , geometry , biological activity
An overview is provided regarding the different use of in vitro dissolution and particular related regulatory aspects. The overview attempts to clarify the regulatory requirements in all contexts in which in vitro dissolution data are employed. The different areas comprise the development of new and generic products as well as bioequivalence between different formulations. In vitro dissolution is no longer one issue among others in terms of specifications and batch release only, but is aimed to be a relevant tool for describing biopharmaceutic product characteristics for different purposes in the regulatory environment. Accordingly, the extent of the experiments will depend on the purpose of the in vitro dissolution data. Copyright © 2013 John Wiley & Sons, Ltd.